Kite Pharma (KITE) Posts Q4 Loss of 85c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Jefferies Reiterates Buy on Kite Pharma (KITE) Following a Mixed 4Q - PT to $75
March 1, 2016 9:31 AM ESTJefferies maintained a Buy rating on Kite Pharma (NASDAQ: KITE), and cut the price target to $75.00 (from $92.00), following the company's 4Q earnings conference call. KITE reported Q4 revenues of $4.9M, coming in ahead of Jefferies' estimate of $4.4M. GAAP EPS of ($0.85) also beat estimates... More
Citi Starts Kite Pharma (KITE) at Buy
February 25, 2016 8:25 AM ESTCiti initiatesd coverage on Kite Pharma (NASDAQ: KITE) with a Buy rating and a price target of $67.00.
For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.
Shares of Kite Pharma closed at $44.97 yesterday.
... More